Heart transplantations at the Heart Center IKEM, Prague, Czech Republic
Language English Country United States Media print
Document type Journal Article
PubMed
23721016
Knihovny.cz E-resources
- MeSH
- Atherosclerosis epidemiology MeSH
- Child MeSH
- Adult MeSH
- Transplantation, Homologous MeSH
- Incidence MeSH
- Infections epidemiology MeSH
- Middle Aged MeSH
- Humans MeSH
- Adolescent MeSH
- Young Adult MeSH
- Neoplasms epidemiology MeSH
- Heart-Assist Devices statistics & numerical data trends MeSH
- Child, Preschool MeSH
- Graft Rejection epidemiology mortality therapy MeSH
- Aged MeSH
- Heart Failure epidemiology mortality surgery MeSH
- Heart Transplantation mortality statistics & numerical data trends MeSH
- Patient Selection MeSH
- Academic Medical Centers statistics & numerical data MeSH
- Tissue and Organ Procurement statistics & numerical data trends MeSH
- Check Tag
- Child MeSH
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Adolescent MeSH
- Young Adult MeSH
- Male MeSH
- Child, Preschool MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Geographicals
- Czech Republic epidemiology MeSH
The heart transplant program at the Institute for Clinical and Experimental Medicine in Prague was established on January 31, 1984. Through November 2012, 881 orthotopic cardiac transplantations have been performed, with an annual rate of about 40 procedures. Current legislation concerning solid organ transplantations in the Czech Republic is described. Like other centers, we have noticed an increasing age of donors, and, reflecting the shortage of grafts, we have expanded our selection criteria for heart transplantation. The advent of a mechanical circulatory support program at our center in April 2003 has given us another valuable tool in the management of chronic heart failure patients. Currently, around half of our patients are transplanted from mechanical support. Nonischemic etiology of heart failure is a leading cause of transplantation at our center, followed by ischemic cardiomyopathy, valvular heart lesions, and adult congenital heart diseases. Our current immunosupression protocol, including induction therapy, is outlined in detail and survival rates, as well as most common complications and our treatment strategies, are also discussed.